News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Clinical

Latest News

June 28th 2019

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma

Patient Cost Implications in Multiple Myeloma Treatment

Treatment Options in Relapsed/Refractory Multiple Myeloma

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

Latest Videos

Dr C. Ola Landgren on Getting Groundbreaking Research Into the Clinic Faster

Dr C. Ola Landgren on Getting Groundbreaking Research Into the Clinic Faster

Dr Adam Olszewski Discusses Challenges With Using Ibrutinib as a First-Line Therapy in CLL

Dr Adam Olszewski Discusses Challenges With Using Ibrutinib as a First-Line Therapy in CLL

Dr Ruben Mesa on Fedratinib's Impact on Health-Related Quality of Life in Myelofibrosis

Dr Ruben Mesa on Fedratinib's Impact on Health-Related Quality of Life in Myelofibrosis

Dr Lena Winestone Outlines Barriers to Care and Disparities Among Children With Leukemia

Dr Lena Winestone Outlines Barriers to Care and Disparities Among Children With Leukemia

Dr Sarah Tasian Highlights Exciting New Advances Coming to Pediatric AML

Dr Sarah Tasian Highlights Exciting New Advances Coming to Pediatric AML

Dr C. Ola Landgren: MRD Is a Growing Topic of Interest in Cancer

Dr C. Ola Landgren: MRD Is a Growing Topic of Interest in Cancer

Dr Ruben Mesa on the Importance of Gauging Quality of Life in MPNs

Dr Ruben Mesa on the Importance of Gauging Quality of Life in MPNs

Dr Lena Winestone Highlights Impact Neighborhood Has on Outcomes in Pediatric Cancer

Dr Lena Winestone Highlights Impact Neighborhood Has on Outcomes in Pediatric Cancer

Dr Abby Statler Discusses Restrictive Criteria Excluding Minority Patients From AML Trials

Dr Abby Statler Discusses Restrictive Criteria Excluding Minority Patients From AML Trials

Dr Lindsey Roeker on Using MRD for Decision Making

Dr Lindsey Roeker on Using MRD for Decision Making

CME Content

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

More News

The Impact of OCM in the Treatment of Multiple Myeloma

June 28th 2019

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

June 28th 2019

MAIA Trial: Transplant-Ineligible Patients With MM

June 28th 2019

Using MRD Negativity to Stop Maintenance Therapy in MM

June 28th 2019

Long-term Data on Improving OS for Patients With MM

June 28th 2019

Payer Perspective: Transplant and Toxicities in MM Therapy

June 28th 2019

FORTE Trial: Transplant in Patients with Multiple Myeloma

June 28th 2019

Impact of Maintenance Therapy in Multiple Myeloma

June 28th 2019

Strategy for Up-front Therapy of Multiple Myeloma

June 28th 2019

Backbone Therapy in Newly Diagnosed Multiple Myeloma

June 28th 2019

How Real-World Data Can Address Problems in MM

June 28th 2019

Dosing Strategies in Relapsed-Refractory MM

June 28th 2019

Initiating Treatment in Relapsed-Refractory MM

June 28th 2019

What Is the Cost of Recurrence in Multiple Myeloma?

June 28th 2019

Daratumumab in the Treatment Landscape for MM

June 28th 2019

Clinical Significance of MRD Testing in MM

June 28th 2019

Practical Implications of the MAIA Study for MM

June 28th 2019

Considerations for Transplant-Ineligible Patients

June 28th 2019

NCCN Guidelines for Newly Diagnosed MM

June 28th 2019

Achieving the Best Outcomes for Patients With MM

June 28th 2019

Cost Considerations of Multidrug Regimens in MM

June 28th 2019

Factoring Age Into Frontline Therapy for MM

June 28th 2019

Individualizing Therapy for Multiple Myeloma Patients

June 28th 2019

June Halper Outlines the Biggest Management Challenges in Multiple Sclerosis

By

June 22nd 2019

The biggest clinical challenges that we have in treating multiple sclerosis are 2-fold, explained June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.

Evaluating Use of Bone-Modifying Agents to Treat Skeletal-Related Events in Cancer

ByLaura Joszt, MA

June 15th 2019

Skeletal-related events are frequent complications in patients with cancers. Two abstracts analyzed the use of bone-modifying agents in patients with newly diagnosed multiple myeloma and breast cancer.

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

5 Things to Know About the Oral GLP-1 Era

Exploring Identity, Appearance Experiences Among Patients With Alopecia

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text